Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Curis second quarter net loss increases to $4.9 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2011.

28 Jul 2011

CEL-SCI expands licensing agreement with Teva for Multikine cancer drug

CEL-SCI Corporation announced today that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine.

20 Jul 2011

Roche signs agreement to acquire mtm laboratories

Ventana Medical Systems, Inc., a member of the Roche Group, announced today that Roche has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany.

From Roche Sequencing and Life Science 19 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

Study reveals link between HPV infection and SCC in organ transplant recipients

A new study published in the American Journal of Transplantation reveals an association between the human papillomavirus (betaPV) infection and cutaneous squamous cell carcinoma (SCC) in organ transplant recipients.

13 Jul 2011

Study finds link between genetic variation and cetuximab rectal cancer therapy

team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery.

7 Jul 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

IsoRay announces combination therapy study for prostate cancer

IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.

20 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

VARI researchers discover protein linked to spread of head and neck cancer nasopharyngeal carcinoma

In a study recently published in Cancer Research, Van Andel Research Institute (VARI) researchers found a protein that could help predict the spread of the head and neck cancer nasopharyngeal carcinoma (NPC); this protein could also serve as part of a treatment strategy to stop the spread of the disease.

15 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Second course of treatment could cure head and neck cancer

A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer.

13 Jun 2011

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

Hundreds of surfers, cancer survivors and friends will gather together, with surfboards in hand, on La Jolla Shores Sunday, June 19 for an annual San Diego tradition: Survivor Beach. Attendees will place surfboards along the edge of the shore, nose-to-tail, from Scripps Pier down La Jolla Shores, with the goal of forming a record-breaking line of several hundred surfboards.

13 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

CEL-SCI Corporation today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM H1N1 activated dendritic cells to treat the H1N1 virus.

27 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

ASTRO to honor two radiation oncologists with 2011 Gold Medal award

The American Society for Radiation Oncology has selected K. Kian Ang, MD, PhD, FASTRO, and Bernard Cummings, MB, ChB, FASTRO, as the Society's 2011 Gold Medal recipients.

26 May 2011

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.

20 May 2011

Head and Neck Cancer News and Research

Curis second quarter net loss increases to $4.9 million

CEL-SCI expands licensing agreement with Teva for Multikine cancer drug

Roche signs agreement to acquire mtm laboratories

CVS Caremark adds Access' MuGard to pharmacy benefit network

Study reveals link between HPV infection and SCC in organ transplant recipients

Study finds link between genetic variation and cetuximab rectal cancer therapy

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

IsoRay announces combination therapy study for prostate cancer

RHEI receives Chinese SFDA acceptance letter for MuGard

VARI researchers discover protein linked to spread of head and neck cancer nasopharyngeal carcinoma

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Second course of treatment could cure head and neck cancer

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

NYU Cancer Institute scientists present new research findings at ASCO 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

ASTRO to honor two radiation oncologists with 2011 Gold Medal award

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News